Novavax Inc
Here’s whether Novavax Inc (NVAX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +17.2%; rising volume confirms the move (1.26x 30d avg). Concerns: 50-day MA is falling (-3.56% over 10 days); RSI 77 — overbought, elevated pullback risk. Currently 25.3% off its 52-week high. Score: +3/7.
NVAX is in a confirmed uptrend, trading above both its 50-day ($8.46) and 200-day ($8.44) moving averages. With an RSI of 76.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +17.2% compares to +20.5% for SPY (trailed the market by 3.3%). The current 25.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.